Surgery-based treatment and prognostic factors in patients with limited-stage small cell lung cancer: a retrospective cohort study - Top-Institutions - MDSpire

Surgery-based treatment and prognostic factors in patients with limited-stage small cell lung cancer: a retrospective cohort study

  • By

  • Mingbo Wang

  • Heng Zhao

  • Yuefeng Zhang

  • Huilai Lv

  • Qin Chu

  • Yonggang Zhu

  • Chunyue Gai

  • Ziqiang Tian

  • May 13, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Georgetown University’s Lombardi Comprehensive Cancer Center
    Georgetown University’s Lombardi Comprehensive Cancer Center

    Washington, DC

    Key Differentiators

    • Oncology

  • #2

    Amsterdam University Medical Center, Cancer Center Amsterdam
    Amsterdam University Medical Center, Cancer Center Amsterdam

    Amsterdam, North Holland

    Key Differentiators

    • Oncology

  • #3

    Fourth Hospital of Hebei Medical University
    Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei

    Key Differentiators

    • Oncology

  • #4

    National Cancer Center, Japan
    National Cancer Center, Japan

    Tokyo, Tokyo

    Key Differentiators

    • Oncology

  • #5

    Medical University of Vienna
    Medical University of Vienna

    Vienna, Vienna

    Key Differentiators

    • Oncology

Original Source(s)

Surgery-based treatment and prognostic factors in patients with limited-stage small cell lung cancer: a retrospective cohort study

  • by Mingbo Wang, Heng Zhao, Yuefeng Zhang, Huilai Lv, Qin Chu, Yonggang Zhu, Chunyue Gai, Ziqiang Tian

  • May 13, 2026

Related Content

Case Report: Dramatic response to amivantamab plus chemotherapy in EGFR G719A–mutant lung adenocarcinoma with liver and peritoneal metastases

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Organ-specific pre-metastatic and metastatic niches in colorectal cancer: “discrepancy in response to immune checkpoint inhibitors in liver and lung metastasis”